HomeInvestors HealthTransMedics up 6% as 2025 revenue guidance exceeds consensus

TransMedics up 6% as 2025 revenue guidance exceeds consensus

February 28, 2025

TransMedics (NASDAQ:TMDX) is ~6% higher in after-hours trading Thursday after posting 2025 revenue guidance above the consensus figure.
The medtech sees revenue this year of $530M-$552M. Consensus is $521.62M.
In Q4, TransMedics (NASDAQ:TMDX) beat on both lines.
In the quarter, net

latest articles